期刊文献+

心脏彩超下右心结构及收缩功能参数与肺动脉高压患者靶向治疗效果的相关性分析

下载PDF
导出
摘要 目的:探讨心脏彩超下右心结构及收缩功能参数与肺动脉高压(PAH)患者靶向治疗效果的相关性。方法:回顾性分析2019年6月—2021年2月在本院住院治疗的PAH患者60例,根据其靶向治疗效果分为总有效组(n=45)和无效组(n=15),比较两组患者临床资料,采用Logistic回归分析影响患者靶向治疗效果的相关因素,ROC分析参数预测PAH患者靶向治疗效果。结果:临床资料比较显示,两组患者右心结构参数大动脉短轴段主肺动脉内径(MPA)、右心室游离壁厚度(RVWT)、右心室基底横径(RVd)及右心房左右径(RAd)及右心收缩功能参数舒张末期至收缩末期三尖瓣环位移(TAPSE)存在明显差异(P<0.05);Logistic回归分析显示RVd1(OR=1.754,P<0.05)、RVd2(OR=0.481,P<0.05)、RAd(OR=1.855,P<0.05)数值上升、TAPSE(OR=1.984,P<0.05)值下降为PAH靶向治疗无效的独立影响因素(P<0.05);ROC曲线分析显示,RVd1、RVd2、RAd、TAPSE预测PAH患者靶向治疗效果的AUC分别为0.819、0.827、0.871、0.908。结论:右心结构参数提高及收缩功能参数降低为导致PAH患者靶向治疗无效的独立影响因素,临床可根据各参数水平变化评估PAH患者靶向治疗效果。
出处 《医学理论与实践》 2022年第18期3171-3173,共3页 The Journal of Medical Theory and Practice
  • 相关文献

参考文献6

二级参考文献35

  • 1傅毅.美国心力衰竭的诊断和治疗指南[J].世界临床药物,2005,26(10):582-585. 被引量:13
  • 2Galie N, Humbert M, Vachiery JL, et al. 2015 ESC/ERSGuidelines for the diagnosis and treatment of pulmonaryhypertension : The Joint Task Force for the Diagnosis andTreatment of Pulmonary Hypertension of the European Society ofCardiology ( ESC) and the European Respiratory Society ( ERS):Endorsed by: Association for European Paediatric and CongenitalCardiology ( AEPC ),International Society for Heart and LungTransplantation (ISHLT) [ J]. Eur Respir J, 2016,37 (1 ) :67-119. DOI: 10. 1093/eurheartj/ehv317.
  • 3Meyer S, McLaughlin VV, Seyfarth HJ, et al. Outcomes ofnoncardiac,nonobstetric surgery in patients with PAH : aninternational prospective survey[ J]. Eur Respir J,2013 , 41 (6):1302-1307. DOI: 10. 1183/09031936.00089212.
  • 4Preston RJ, Roberts KE, Miller DP, et al. Effect of warfarintreatment on survival of patients with pulmonary arterialhypertension ( PAH) in the Registry to Evaluate Early and Long-Term PAH Disease Management ( REVEAL) [ J ]. Circulation,2015,132 ( 25 ) : 2403-2411. DOI: 10. 1161/CIRCULATIONAHA. U5.018435.
  • 5Ruiter G,Lankhorst S, Boonstra A, et al. Iron deficiency iscommon in idiopathic pulmonary arterial hypertension [ J ]. EurRespir J, 2011 , 37(6) : 1386-1391. DOI: 10.1183/09031936.00100510.
  • 6Rhodes CJ, Howard LS, Busbridge M, et al. Iron deficiency andraised hepcidin in idiopathic pulmonary arterial hypertensionclinical prevalence,outcomes,and mechanistic insights [ J ]. JAm Coll Cardiol, 2011’ 58(3): 300-309. DOI: 10. 1016/j.jacc. 2011.02.057.
  • 7Ghofrani HA , Galie N, Grimminger F, et al. Riociguat for thetreatment of pulmonary arterial hypertension[ J]. N Engl J Med,2013,369(4) : 330-340. DOT: 10. 1056/NEJMoal209655.
  • 8McLaughlin VV, Channick R, Chin KM, et al. Effect ofselexipag on morbidity/mortality in pulmonary arterialhypertension : results of the GRIPHON study [ J ]. J Am CollCardiol, 2015, 65 ( 10): A1538. DOI: 10. 1016/S0735-1097(15)61538-8.
  • 9Kurzyna M, Dabrowski M, Bielecki D, et al. Atrial septostomy intreatment of end-stage right heart failure in Patients withpulmonary hypertension [ J ]. Chest, 2007,131 (4): 977-983.DOI: 10. 1378/chest. 06-1227.
  • 10Hoeper MM, Granton J. Intensive care unit management ofpatients with severe pulmonary hypertension and right heart failure[J]. Am J Respir Crit Care Med, 2011, 184(10) : 1114-1124.DOI: 10. 1164/rccm. 201104-0662CI.

共引文献57

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部